Previous 10 | Next 10 |
Allogeneic (off the shelf) iNKT cell therapy targets patients with moderate to severe COVID-19 iNKT cells designed to clear SARS-CoV-2 virus while reducing harmful inflammation LEXINGTON, Mass., Nov. 02, 2020 (GLOBE NEWSWIRE) -- Agenus Inc. (NASDAQ: AGEN), an immuno-oncology com...
Image source: The Motley Fool. Agenus Inc (NASDAQ: AGEN) Q3 2020 Earnings Call Oct 29, 2020 , 8:30 a.m. ET Operator Continue reading For further details see: Agenus Inc (AGEN) Q3 2020 Earnings Call Transcript
Agenus Inc. (AGEN) Q3 2020 Earnings Conference Call October 29, 2020 08:30 AM ET Company Participants Jennifer Buell - President & Chief Operating Officer Garo Armen - Chairman & Chief Executive Officer Christine Klaskin - Vice President of Finance Conference Call Participants Mayank ...
Agenus ([[AGEN]] -3.8%) Q3 results:Revenues: $14.83M (-25.6% Y/Y) vs consensus of $14M.Net loss: ($52M); loss/share: ($0.28)CF Ops: ($32M) (-14.3%).Key Upcoming Milestones: Balstilimab rolling BLA filing and FDA review underway.COVID-19 trial open with patients in screening for...
Agenus (AGEN): Q3 GAAP EPS of -$0.28 misses by $0.02.Revenue of $14.83M (-25.6% Y/Y) beats by $0.83M.Press Release For further details see: Agenus EPS misses by $0.02, beats on revenue
Balstilimab rolling BLA filing and FDA review underway COVID-19 trial open with patients in screening for iNKT Cell Therapy New data and clinical responses with AGEN1181 to be presented at SITC on NOV11 LEXINGTON, Mass., Oct. 29, 2020 (GLOBE NEWSWIRE) -- Agenus Inc. (NASDA...
LEXINGTON, Mass., Oct. 20, 2020 (GLOBE NEWSWIRE) -- Agenus Inc. (NASDAQ: AGEN), an immuno-oncology company with an extensive pipeline of checkpoint antibodies, cell therapy, adjuvants, and vaccines designed to activate immune response to cancers and infections, today announced it will relea...
Clinical Responses : AGEN1181 (Fc-enhanced anti-CTLA-4) +/- balstilimab Clinical Data : Zalifrelimab efficacy in refractory rare tumors Clinical & Preclinical Data : AGEN 2373 (anti-CD137) Phase 2 Data: Optimizing treatment with bals...
LEXINGTON, Mass., Oct. 13, 2020 (GLOBE NEWSWIRE) -- Agenus Inc. (NASDAQ: AGEN), an immuno-oncology company with an extensive pipeline of checkpoint antibodies, cell therapy, adjuvants, and vaccines designed to activate immune response to cancers and infections, today announced the election ...
Agenus's balstilimab and zalifrelimab nears FDA submission for cervical cancer. Seattle Genetics presented tisotumab vedotin cervical cancer data at ESMO. They may compete in the marketplace despite differing mechanisms of action. For further details see: Agenus Vs. Seat...
News, Short Squeeze, Breakout and More Instantly...
Agenus Inc. (“Agenus”) (Nasdaq: AGEN), a leader in developing novel immunological agents to treat various cancers, today announced the Company will release its second quarter 2024 financial results before the market opens on Thursday, August 8, 2024. Agenus executives will host a co...
A look at the top 10 most actives in the United States Onconetix Inc. (ONCO) rose 46.5% to $0.2183 on volume of 404,016,812 shares NVIDIA Corporation (NVDA) rose 2.6% to $121.09 on volume of 317,123,916 shares PROSHARES TRUST (SQQQ) rose 1.5% to $8.23 on volume of 207,449,647 shares Max...
2024-07-18 12:11:22 ET Agenus Inc (NASDAQ: AGEN) faced a dramatic decline in its stock price on Thursday, plummeting more than 50%, following the US Food and Drug Administration (FDA’s) decision to advise against pursuing accelerated approval for its BOT/BAL colorectal cance...